Bracco Company Profile

What is the competitive landscape for BRACCO

BRACCO has forty-three approved drugs.

There are three US patents protecting BRACCO drugs.

There are forty-five patent family members on BRACCO drugs in thirteen countries and eighty-four supplementary protection certificates in nine countries.

Summary for Bracco

International Patents:	45
US Patents:	3
Tradenames:	66
Ingredients:	33
NDAs:	43

Drugs and US Patents for Bracco

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bracco	IODOTOPE	sodium iodide i-131	SOLUTION;ORAL	010929-002	Approved Prior to Jan 1, 1982		DISCN	No	No
Bracco	MULTIHANCE	gadobenate dimeglumine	INJECTABLE;INTRAVENOUS	021357-004	Nov 23, 2004		RX	Yes	Yes
Bracco	CARDIOGRAFIN	diatrizoate meglumine	INJECTABLE;INJECTION	011620-002	Approved Prior to Jan 1, 1982		DISCN	No	No
Bracco	CHOLOVUE	iodoxamate meglumine	INJECTABLE;INJECTION	018077-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Bracco	IOMERVU	iomeprol	SOLUTION;INTRAVENOUS	216017-005	Nov 27, 2024		DISCN	Yes	No

Expired US Patents for Bracco

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Bracco	ISOVUE-370	iopamidol	INJECTABLE;INJECTION	018735-003	Dec 31, 1985	4,001,323
Bracco	ISOVUE-370	iopamidol	INJECTABLE;INJECTION	020327-004	Oct 12, 1994	4,001,323
Bracco	MULTIHANCE	gadobenate dimeglumine	INJECTABLE;INTRAVENOUS	021357-001	Nov 23, 2004	4,916,246
Bracco	LUMASON	sulfur hexafluoride lipid-type a microspheres	FOR SUSPENSION;INTRAVENOUS	203684-001	Oct 15, 2014	5,686,060
Bracco	CHOLOVUE	iodoxamate meglumine	INJECTABLE;INJECTION	018076-001	Approved Prior to Jan 1, 1982	3,654,272

International Patents for Bracco Drugs

Country	Patent Number	Estimated Expiration
Japan	2022532344
Mexico	2020012604
Japan	7357078
Israel	288094
Canada	3137089

Supplementary Protection Certificates for Bracco Drugs

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1856135	2020/017	Ireland		PRODUCT NAME: FOSTAMATINIB OR A PHARMACEUTICALLY ACCEPTABLE SALT OF FOSTAMATINIB, OR A HYDRATE, SOLVATE OR N-OXIDE OF FOSTAMATINIB OR THE PHARMACEUTICALLY ACCEPTABLE SALT OF FOSTAMATINIB, ESPECIALLY FOSTAMATINIB DISODIUM, OPTIONALLY IN FORM OF A HYDRATE; REGISTRATION NO/DATE: EU/1/19/1405 20200113
1912999	14C0076	France		PRODUCT NAME: SIMEPREVIR OU L'UN DE SES SELS, INCLUANT LE SEL DE SODIUM DE SIMEPREVIR; REGISTRATION NO/DATE: EU/1/14/924 20140516
2203431	1590018-6	Sweden		PRODUCT NAME: DASABUVIR OR A SALT THEREOF, INCLUDING DASABUVIR SODIUM MONOHYDRATE; REG. NO/DATE: EU/1/14/983 20150119
2340828	LUC00195	Luxembourg		PRODUCT NAME: SACUBITRIL ET VALSARTAN, SOUS FORME DE COMPLEXE DE SEL DE SODIUM SACUBITRIL VALSARTAN, C'EST-A-DIRE (((S)-N-VALERYL-N-((2'-(1H-TETRAZOLE-5-YL)-BIPHENYL-4-YL)-METHYL)-VALINE) ((2R,4S)-5-BIPHENYL-4-YL-4-(3-CARBOXY-PROPIONYLAMINO)-2-METHYL-ESTER ETHYLIQUE D'ACIDE PENTANOIQUE))NA3 X H2O, DANS LEQUEL X EST 0 A 3; AUTHORISATION NUMBER AND DATE: EU/1/15/1058 20151123
1856135	LUC00153	Luxembourg		PRODUCT NAME: FOSTAMATINIB OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE FOSTAMATINIB, OU UN HYDRATE, SOLVATE OU N-OXYDE DE FOSTAMATINIB OU LE SEL PHARMACEUTIQUEMENT ACCEPTABLE DE FOSTAMATINIB, EN PARTICULIER FOSTAMATINIB DISODIUM, EVENTUELLEMENT SOUS FORME D'HYDRATE; AUTHORISATION NUMBER AND DATE: EU/1/19/1405 20200113

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Bracco

Bracco: Market Position, Strengths & Strategic Insights

Last updated: February 19, 2026

Bracco S.p.A. holds a significant position in the diagnostic imaging sector, primarily focusing on contrast agents for radiology and ultrasound. The company’s market strategy centers on innovation in contrast media, development of imaging equipment, and expansion of its service offerings. Key competitive factors include product portfolio breadth, patent protection, regulatory approvals, and strategic partnerships.

What is Bracco's Core Business and Market Focus?

Bracco's core business is the development, manufacturing, and marketing of diagnostic imaging solutions. This encompasses a range of contrast agents, radiopharmaceuticals, medical devices for their administration, and ultrasound equipment. The company’s primary market focus is on enhancing the visualization of internal body structures to aid in the diagnosis of various medical conditions.

Bracco operates across several key diagnostic imaging modalities:

• X-ray and Computed Tomography (CT): Bracco is a major supplier of iodinated contrast media for these procedures.
• Magnetic Resonance Imaging (MRI): The company provides gadolinium-based contrast agents.
• Ultrasound: Bracco offers ultrasound contrast agents and equipment.
• Nuclear Medicine: Bracco supplies radiopharmaceuticals used in PET and SPECT imaging.

The company’s strategic emphasis is on providing integrated solutions, moving beyond standalone products to offer comprehensive diagnostic packages. This approach aims to address the evolving needs of healthcare providers for more accurate, efficient, and patient-friendly diagnostic tools.

How is Bracco Positioned in the Global Contrast Media Market?

Bracco is a leading player in the global contrast media market, competing with major pharmaceutical and chemical companies. The market for contrast agents is characterized by high regulatory barriers, significant R&D investment, and a need for specialized manufacturing capabilities.

Key Market Share and Competitive Landscape:

The global contrast media market is estimated to be worth billions of dollars, with growth driven by an aging population, increasing incidence of chronic diseases, and advancements in imaging technologies.

• Bracco’s Market Share: While exact, consistently updated market share figures are proprietary, Bracco is consistently ranked among the top three global suppliers of contrast media, alongside GE HealthCare and Bayer AG [1].
• Product Portfolio: Bracco has a comprehensive portfolio of contrast agents for various modalities, including:
  • Iodinated Contrast Media: Products like Gastrografin and Xenon are widely used in X-ray and CT imaging.
  • Gadolinium-Based Contrast Agents (GBCAs): Used in MRI, with products like Gadovist (developed by Bayer but marketed by Bracco in some regions through licensing agreements) being a significant competitor, and Bracco's own offerings in this space.
  • Ultrasound Contrast Agents: Such as SonoVue, which enhances echogenicity for diagnostic purposes.
  • Radiopharmaceuticals: For PET and SPECT imaging.
• Competitive Advantages: Bracco leverages its strong historical presence, established distribution networks, and a continuous focus on product development.

Table 1: Major Players in the Contrast Media Market

Company	Key Product Areas	Primary Modalities Supported	Notes
Bracco S.p.A.	Iodinated Contrast Media, Gadolinium Agents, Ultrasound Agents, Radiopharmaceuticals	X-ray, CT, MRI, Ultrasound, Nuclear Medicine	Strong R&D focus, integrated solutions provider, global manufacturing and distribution.
GE HealthCare	Iodinated Contrast Media, Gadolinium Agents	X-ray, CT, MRI	Extensive imaging equipment portfolio, significant market presence.
Bayer AG	Iodinated Contrast Media, Gadolinium Agents	X-ray, CT, MRI	Strong R&D pipeline, established brand recognition, broad pharmaceutical presence.
Siemens Healthineers	Primarily imaging equipment, some contrast agent distribution	X-ray, CT, MRI, Ultrasound	Focus on integrated imaging and IT solutions; contrast agent offerings are often complementary.

Bracco's strategy involves expanding its offerings beyond contrast agents to include related diagnostic equipment and services, aiming for a more integrated diagnostic workflow for healthcare providers.

What are Bracco's Key Strengths and Competitive Advantages?

Bracco's competitive strengths are rooted in its deep specialization, robust intellectual property, and strategic partnerships.

• Specialization in Contrast Media: Bracco has focused on contrast agents for decades, building deep expertise in their development, manufacturing, and application. This specialization allows for targeted innovation and efficient production.
• Robust Patent Portfolio: The company holds a significant number of patents covering novel contrast agent formulations, delivery systems, and manufacturing processes. These patents provide a crucial barrier to entry for competitors and secure market exclusivity for new products. For example, patents related to specific chemical structures of contrast agents or improved solubility and safety profiles are vital.
• Global Manufacturing and Distribution Network: Bracco operates manufacturing facilities across Europe, North America, and Asia. This global presence ensures reliable supply chains, allows for adaptation to regional regulatory requirements, and facilitates efficient distribution to key markets.
• Innovation Pipeline: Bracco invests heavily in research and development, aiming to introduce next-generation contrast agents with improved safety profiles, efficacy, and new diagnostic capabilities. This includes research into novel molecular targets and imaging techniques.
• Strategic Partnerships and Collaborations: The company engages in collaborations with academic institutions, research organizations, and other industry players. These partnerships accelerate R&D, expand market access, and foster the development of integrated diagnostic solutions. Examples include collaborations for the development of new radiopharmaceuticals or advanced ultrasound technologies.
• Regulatory Expertise: Navigating the complex and stringent regulatory pathways for pharmaceutical products is a significant strength. Bracco has a proven track record of obtaining approvals from major regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).
• Integrated Diagnostic Solutions: Bracco is increasingly positioning itself as a provider of integrated solutions, combining contrast agents with imaging equipment and software. This approach offers a value proposition to healthcare providers by streamlining workflows and improving diagnostic accuracy.

What are the Key Technologies and Product Innovations Driving Bracco's Growth?

Bracco's growth is propelled by continuous innovation in contrast media technology and the development of advanced diagnostic tools.

• Advanced Iodinated Contrast Agents: Bracco continues to refine its iodinated contrast agents for X-ray and CT. Innovations focus on reducing the risk of adverse events, improving image quality at lower doses, and developing agents suitable for specific patient populations (e.g., those with renal impairment). Examples include high-osmolar and low-osmolar agents tailored for different clinical needs.
• Next-Generation Gadolinium-Based Contrast Agents (GBCAs): For MRI, Bracco is involved in developing GBCAs with enhanced safety profiles, addressing concerns about gadolinium retention in the body. Research focuses on optimizing molecular structure to improve excretion and minimize deposition.
• Ultrasound Contrast Agents: The development of microbubble-based ultrasound contrast agents, such as SonoVue, has been a significant innovation. These agents improve the visualization of blood flow and tissue perfusion, enabling more accurate diagnoses in areas like cardiology and hepatology. Future developments may focus on targeted contrast agents that accumulate in specific tissues or pathologies.
• Radiopharmaceuticals for Molecular Imaging: Bracco is expanding its portfolio of radiopharmaceuticals used in PET and SPECT imaging. This involves developing new tracers that can detect specific molecular targets associated with diseases like cancer or neurological disorders. The integration of molecular imaging with anatomical imaging is a key trend.
• Smart Delivery Systems: The company is also investing in smart injection systems and software that optimize contrast agent administration, ensuring accurate dosing and timing for improved image acquisition. This includes connected devices and AI-driven software for dose optimization.
• Artificial Intelligence (AI) in Diagnostics: Bracco is exploring the integration of AI with its diagnostic solutions. This can involve AI algorithms for image analysis, dose optimization, and workflow management, further enhancing the value proposition of its products.

Table 2: Key Bracco Product Innovations and Technologies

Technology Area	Product Example(s) / Focus	Clinical Application	Innovation Driver
Iodinated Contrast Media	Gastrografin, Xenon	X-ray, CT imaging (gastrointestinal, vascular)	Improved safety, reduced viscosity, enhanced image quality at lower doses.
Gadolinium-Based Contrast Agents	(Focus on safety and efficacy)	MRI imaging (vascular, tissue characterization)	Minimizing gadolinium deposition, enhanced relaxivity.
Ultrasound Contrast Agents	SonoVue	Ultrasound imaging (cardiac, hepatic, renal perfusion)	Improved echogenicity, longer persistence, potential for targeted delivery.
Radiopharmaceuticals	(Focus on novel tracers for PET/SPECT)	Molecular imaging for oncology, neurology, cardiology	Detection of specific biomarkers, earlier disease diagnosis.
Smart Delivery Systems	Automated injectors, software for dose management	Optimized contrast agent administration for various imaging modalities	Enhanced patient safety, improved workflow efficiency, consistent image quality.
AI Integration	AI-powered image analysis, dose optimization algorithms	Enhancing diagnostic accuracy, streamlining clinical workflows	Leveraging big data for improved diagnostic insights and operational efficiency.

What are Bracco's Strategic Imperatives and Future Outlook?

Bracco's strategic imperatives are focused on sustained innovation, market expansion, and the development of integrated diagnostic solutions in response to evolving healthcare demands.

• Continued R&D Investment: Bracco will continue to prioritize investment in R&D to maintain its leadership in contrast media and expand into new diagnostic areas. This includes research into targeted therapies, novel imaging techniques, and advanced formulations.
• Geographic Expansion: While strong in established markets, Bracco seeks to deepen its penetration in emerging economies, particularly in Asia and Latin America, where healthcare infrastructure is rapidly developing and demand for advanced diagnostics is rising.
• Integration of Solutions: The company’s strategy of offering integrated diagnostic solutions – combining contrast agents, equipment, and software – will be a key driver. This approach addresses the healthcare industry’s need for streamlined, efficient, and high-quality diagnostic pathways.
• Focus on Patient Safety and Efficacy: With increasing scrutiny on the safety of diagnostic agents, Bracco will continue to emphasize the development of products with superior safety profiles and efficacy. This includes minimizing adverse events and optimizing diagnostic accuracy.
• Digitalization and AI: Embracing digital technologies, including AI, will be crucial for enhancing product offerings, optimizing manufacturing, and improving customer service. AI can play a role in image analysis, predictive diagnostics, and personalized medicine.
• Strategic Acquisitions and Partnerships: Bracco may pursue targeted acquisitions or form strategic alliances to accelerate its entry into new therapeutic areas or to acquire complementary technologies and market access.
• Addressing Regulatory Landscapes: Proactively managing evolving regulatory requirements globally and adapting to new guidelines for drug development and marketing will remain a critical strategic focus.

The future outlook for Bracco is positive, driven by its established market position, commitment to innovation, and strategic alignment with global healthcare trends. The increasing demand for minimally invasive diagnostics, early disease detection, and personalized medicine positions Bracco's specialized portfolio for continued growth.

Key Takeaways

Bracco S.p.A. is a preeminent global supplier of diagnostic imaging contrast media and solutions. The company's competitive strength lies in its deep specialization, robust patent portfolio, and extensive manufacturing and distribution network. Growth is driven by innovation in advanced contrast agents for X-ray, CT, MRI, and ultrasound, alongside an expanding portfolio of radiopharmaceuticals and integrated diagnostic systems. Strategic imperatives focus on continued R&D, geographic expansion, and the integration of digital technologies, including AI, to enhance patient care and diagnostic efficacy.

FAQs

1. What is Bracco's primary competitive advantage in the contrast media market? Bracco's primary competitive advantage is its deep specialization and decades of focused R&D in contrast media, complemented by a robust patent portfolio and a global manufacturing and distribution infrastructure.

2. How does Bracco differentiate its product offerings in the MRI contrast agent market? Bracco differentiates its MRI contrast agents by focusing on developing next-generation gadolinium-based agents with enhanced safety profiles, aimed at minimizing potential side effects such as gadolinium retention in the body.

3. What role does Bracco play in the burgeoning field of molecular imaging? Bracco contributes to molecular imaging through its development and supply of radiopharmaceuticals for PET and SPECT imaging, creating tracers that can detect specific molecular targets for earlier and more accurate disease diagnosis, particularly in oncology and neurology.

4. In which geographic regions does Bracco see the most significant growth potential? Bracco identifies emerging economies in Asia and Latin America as key regions for significant growth potential due to their rapidly developing healthcare infrastructures and increasing demand for advanced diagnostic solutions.

5. How is Bracco leveraging digital transformation and AI within its business strategy? Bracco is integrating digital transformation and AI to enhance its diagnostic solutions through AI-powered image analysis and dose optimization algorithms, and to improve operational efficiency in manufacturing and customer service.

Citations

[1] Various Market Research Reports on Diagnostic Imaging and Contrast Media. (Dates vary by report).